Sakurai Yuji, Motohashi Hideyuki, Ogasawara Ken, Terada Tomohiro, Masuda Satohiro, Katsura Toshiya, Mori Noriko, Matsuura Motokazu, Doi Toshio, Fukatsu Atsushi, Inui Ken-ichi
Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Kyoto, Japan,
Pharm Res. 2005 Dec;22(12):2016-22. doi: 10.1007/s11095-005-8383-5. Epub 2005 Nov 1.
Our previous studies showed that the mRNA level of human organic anion transporter (hOAT) 3 in the kidney was correlated with the rate of elimination of an anionic antibiotic cefazolin. However, the correlation coefficient was not so high. In the present study, therefore, we enrolled more patients to examine whether additional factors were responsible for the correlation.
hOAT mRNA levels in renal biopsy specimens were quantified using the real-time polymerase chain reaction method. The elimination rates for the free fraction of cefazolin were determined in patients with various renal diseases.
In the present study, the coefficient of correlation between the hOAT3 mRNA level and the elimination rates for the free fraction of cefazolin was not so high in the patients overall as in our previous study (r = 0.536). However, following the classification of renal diseases, a better correlation was obtained in patients with mesangial proliferative glomerulonephritis (r = 0.723). In contrast, multiple regression analyses including gender, age, and liver function did not result in any improvements in the correlation coefficients.
These results suggest that the hOAT3 mRNA level is a significant marker of pharmacokinetics with which to predict the rate of elimination of cefazolin in patients with mesangial proliferative glomerulonephritis.
我们之前的研究表明,人有机阴离子转运体(hOAT)3在肾脏中的mRNA水平与阴离子抗生素头孢唑林的消除率相关。然而,相关系数并不高。因此,在本研究中,我们纳入了更多患者以检查是否有其他因素导致了这种相关性。
使用实时聚合酶链反应方法对肾活检标本中的hOAT mRNA水平进行定量。测定了各种肾脏疾病患者中头孢唑林游离部分的消除率。
在本研究中,hOAT3 mRNA水平与头孢唑林游离部分消除率之间的相关系数在总体患者中不如我们之前的研究高(r = 0.536)。然而,在对肾脏疾病进行分类后,系膜增生性肾小球肾炎患者获得了更好的相关性(r = 0.723)。相比之下,包括性别、年龄和肝功能的多元回归分析并未使相关系数得到任何改善。
这些结果表明,hOAT3 mRNA水平是一种重要的药代动力学标志物,可用于预测系膜增生性肾小球肾炎患者中头孢唑林的消除率。